AstraZeneca PLC - American Depositary Shares (NQ:AZN)

92.77 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

75 76 Next >

Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years ↗

June 04, 2024

Via Benzinga

Large Cap BIopharmaceuticals Overview ↗

June 03, 2024

As a defensive play healthcare is weighted at about 12% of the S&P 500.

Via Talk Markets

Topics Stocks

The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy. ↗

June 03, 2024

There's probably a big enough pie here for everyone to get a slice.

Via The Motley Fool

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

June 02, 2024

From AstraZeneca

Via Business Wire

Stocks Seeing Relentless Buying Pressure; Bonds Are Not ↗

June 02, 2024

Relentless buying pressure, to the degree that we saw in Q4 last year, is evidence of strong underlying demand for stocks. Meanwhile, after a 40-year drawdown, the 50-week rate of change for US 30-year...

Via Talk Markets

Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years ↗

May 22, 2024

Via Benzinga

IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

June 02, 2024

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy

June 02, 2024

From AstraZeneca

Via Business Wire

3 No-Brainer Stocks to Buy in June ↗

June 02, 2024

Now is the time to invest in these great stocks.

Via The Motley Fool

This Pharma Stock Is Poised to Keep Outperforming the S&P 500 ↗

May 30, 2024

AstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company should be able to repeat this feat over the next 10 years.

Via The Motley Fool

Topics Stocks

Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug ↗

May 29, 2024

The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.

Via Benzinga

AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock ↗

May 29, 2024

Both businesses have road maps for the future, but one is better.

Via The Motley Fool

AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock? ↗

May 29, 2024

Its new strategic roadmap aims to catapult the company forward.

Via The Motley Fool

Cellectis Reports Financial Results for First Quarter 2024

May 28, 2024

From Cellectis Inc.

Via GlobeNewswire

Why Is AstraZeneca Stock Trading Lower On Tuesday? ↗

May 28, 2024

AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.

Via Benzinga

AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report ↗

May 27, 2024

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.

Via Benzinga

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

May 27, 2024

From AstraZeneca

Via Business Wire

Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings ↗

May 25, 2024

Via Talk Markets

Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies ↗

May 23, 2024

U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq.

Via Benzinga

Topics Lawsuit

AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)

May 23, 2024

From AstraZeneca

Via Business Wire

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity ↗

May 23, 2024

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later...

Via Benzinga

The RBNZ Maintained Its Hawkish Bias, Leaving The Interest Rate At 5.5% ↗

May 22, 2024

The Reserve Bank of New Zealand kept the official cash rate at 5.5% during its May 2024 policy meeting, extending the rate pause for the 7th straight time and confirming market expectations.

Via Talk Markets

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

May 22, 2024

From AstraZeneca

Via Business Wire

AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion ↗

May 21, 2024

AstraZeneca aims to boost its revenue from $45.8 billion in 2023 to $80 billion by 2030. Key growth drivers include expanding oncology, biopharmaceuticals, rare disease portfolios, and launching 20 new...

Via Benzinga

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

May 21, 2024

From AstraZeneca

Via Business Wire

Large Cap Biopharmaceuticals Performance ↗

May 20, 2024

The biotech sector remains a laggard YTD as can be seen by the IBB.

Via Talk Markets

Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population ↗

May 20, 2024

Amgen and AstraZeneca reveal Phase 2a results for Tezspire in severe COPD, showing a 17% reduction in exacerbations, with notable improvements in lung function and quality of life for patients with...

Via Benzinga

Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute ↗

May 20, 2024

A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment.

Via Benzinga

Topics Intellectual Property

New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease

May 19, 2024

From AstraZeneca

Via Business Wire

AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows ↗

May 16, 2024

AstraZeneca's Phase 3 SUPERNOVA trial shows sipavibart significantly reduces symptomatic COVID-19 in immunocompromised patients. The trial met primary endpoints, showing effectiveness against various...

Via Benzinga

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

75 76 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.